Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Ann Oncol. 2010 May:21 Suppl 5:v223-7. doi: 10.1093/annonc/mdq192.
No abstract available

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Biomarkers, Tumor / metabolism
  • Cytotoxins / therapeutic use
  • Embolization, Therapeutic
  • Europe / epidemiology
  • Female
  • Follow-Up Studies
  • Gastrointestinal Neoplasms / diagnosis*
  • Gastrointestinal Neoplasms / therapy*
  • General Surgery
  • Humans
  • Incidence
  • Interferon-alpha / therapeutic use
  • Male
  • Neoplasm Metastasis / therapy
  • Neoplasm Staging
  • Neuroendocrine Tumors / diagnosis*
  • Neuroendocrine Tumors / pathology
  • Neuroendocrine Tumors / therapy*
  • Pancreatic Neoplasms / diagnosis*
  • Pancreatic Neoplasms / therapy*
  • Risk Assessment
  • Sirolimus / antagonists & inhibitors
  • Sirolimus / therapeutic use
  • Somatostatin / analogs & derivatives
  • Somatostatin / therapeutic use
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Biomarkers, Tumor
  • Cytotoxins
  • Interferon-alpha
  • Somatostatin
  • Sirolimus